Engineered donor cells aim to shield transplant patients from dangerous viruses
NCT ID NCT07672964
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial tests whether giving patients a special type of donor immune cell, called CD45RA-depleted DLI, can prevent serious viral infections after a stem cell transplant. The study includes 30 high-risk patients who have received a transplant for blood cancer. Researchers will monitor for infections like CMV and EBV, and check how well the immune system recovers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD45RA-depleted donor lymphocyte infusion
What this could lead to
If it works, this approach could reduce the risk of life-threatening viral infections after stem cell transplants, improving survival and recovery.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. The treatment itself may cause side effects like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital
Shanghai, SH, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••